MX2017000964A - Compositions and methods of use for treating metabolic disorders. - Google Patents
Compositions and methods of use for treating metabolic disorders.Info
- Publication number
- MX2017000964A MX2017000964A MX2017000964A MX2017000964A MX2017000964A MX 2017000964 A MX2017000964 A MX 2017000964A MX 2017000964 A MX2017000964 A MX 2017000964A MX 2017000964 A MX2017000964 A MX 2017000964A MX 2017000964 A MX2017000964 A MX 2017000964A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- metabolic disorders
- treating metabolic
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462031063P | 2014-07-30 | 2014-07-30 | |
US201562195908P | 2015-07-23 | 2015-07-23 | |
PCT/US2015/042510 WO2016018931A1 (en) | 2014-07-30 | 2015-07-28 | Compositions and methods of use for treating metabolic disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017000964A true MX2017000964A (en) | 2017-09-07 |
MX370115B MX370115B (en) | 2019-12-02 |
Family
ID=55179329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000964A MX370115B (en) | 2014-07-30 | 2015-07-28 | Compositions and methods of use for treating metabolic disorders. |
Country Status (28)
Country | Link |
---|---|
US (3) | US9834586B2 (en) |
EP (1) | EP3174894B1 (en) |
JP (1) | JP6704358B2 (en) |
KR (1) | KR20170065026A (en) |
CN (1) | CN106573966B (en) |
AP (1) | AP2016009663A0 (en) |
AU (1) | AU2015296640B2 (en) |
CA (1) | CA2953827A1 (en) |
CL (1) | CL2017000201A1 (en) |
CO (1) | CO2017000614A2 (en) |
CR (1) | CR20170027A (en) |
DO (1) | DOP2017000025A (en) |
EA (1) | EA035581B1 (en) |
EC (1) | ECSP17005276A (en) |
ES (1) | ES2883158T3 (en) |
IL (1) | IL249793B (en) |
MD (1) | MD20170020A2 (en) |
MX (1) | MX370115B (en) |
MY (1) | MY192917A (en) |
PE (1) | PE20170771A1 (en) |
PH (1) | PH12017500153A1 (en) |
SG (2) | SG11201700378PA (en) |
SV (1) | SV2017005367A (en) |
TN (1) | TN2016000578A1 (en) |
TW (1) | TWI710570B (en) |
UA (1) | UA123432C2 (en) |
WO (1) | WO2016018931A1 (en) |
ZA (1) | ZA201700311B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9714276B2 (en) | 2012-01-26 | 2017-07-25 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) polypeptides |
US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
JP6272907B2 (en) | 2013-01-30 | 2018-01-31 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | Compositions and methods of use in the treatment of metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
EP3099304A4 (en) | 2014-01-31 | 2018-01-10 | Mayo Foundation for Medical Education and Research | Novel therapeutics for the treatment of glaucoma |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
JP6704358B2 (en) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | Compositions and methods of use for treating metabolic disorders |
US9920118B2 (en) * | 2014-10-31 | 2018-03-20 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
JP7021099B2 (en) | 2016-03-31 | 2022-02-18 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | Bound protein and how to use it |
US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
BR112018072034A2 (en) | 2016-05-24 | 2019-02-12 | Novo Nordisk A/S | mic-1 compounds and uses thereof |
EP4056196A1 (en) * | 2016-10-07 | 2022-09-14 | Beth Israel Deaconess Medical Center, Inc. | Compositions comprising relaxin and methods of use thereof |
JOP20190095A1 (en) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors |
JP2020517657A (en) * | 2017-04-20 | 2020-06-18 | ノヴォ ノルディスク アー/エス | Purification method of albumin fusion protein |
JP2020533302A (en) | 2017-09-10 | 2020-11-19 | ノヴォ ノルディスク アー/エス | MIC-1 and GLP-1 for use in the treatment of obesity |
EP3741774A4 (en) | 2018-01-19 | 2021-06-02 | Pepgene Inc. | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same |
TWI724392B (en) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | Growth differentiation factor 15 agonist compounds and methods of using the same |
MX2020010659A (en) | 2018-04-09 | 2020-10-28 | Amgen Inc | Growth differentiation factor 15 fusion proteins. |
KR20210044244A (en) | 2018-08-10 | 2021-04-22 | 노파르티스 아게 | GFRAL extracellular domain and method of use |
US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
CN114651003A (en) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | CA2-IL15 fusion protein for adjustable regulation |
WO2021067655A1 (en) | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
US20230002460A1 (en) * | 2019-11-26 | 2023-01-05 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
JP2023505833A (en) * | 2019-12-11 | 2023-02-13 | エルジー・ケム・リミテッド | Fusion Polypeptides Comprising an O-Glycosylatable Polypeptide Region and GDF15 |
CN115443132A (en) * | 2019-12-12 | 2022-12-06 | 奎拉里斯生物公司 | Controlled delivery of chromancarlin prodrugs |
CN115260313B (en) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Fusion proteins of GLP-1 and GDF15 and conjugates thereof |
WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
FR2650598B1 (en) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO1994003599A1 (en) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
JPH07250688A (en) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | New human c-dna coding tgf-beta superfamily protein |
JPH07258293A (en) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | New protein and its production |
US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
ATE423788T1 (en) | 1995-06-22 | 2009-03-15 | St Vincents Hosp Sydney | NEW TGF-BETA-LIKE CYTOKINE |
US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
JP2001500732A (en) | 1996-09-11 | 2001-01-23 | オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド | TNF-β-like proteins and related nucleic acid molecules, pharmaceutical compositions and methods for treating prostate cancer |
AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
JP2003526322A (en) | 1998-07-23 | 2003-09-09 | スミスクライン ビーチャム コーポレーション | Secreted cysteine-rich protein-6 (scrp-6) |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
EP1179067B1 (en) | 1999-05-17 | 2006-12-13 | BIOPHARM Gesellschaft zur biotechnologischen Entwicklung und zum Vertrieb von Pharmaka mbH | Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily |
GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
CA2404163C (en) * | 2000-03-22 | 2009-09-29 | Octagene Gmbh | Production of recombinant blood clotting factors in human cell lines |
EP2267026A1 (en) | 2000-04-12 | 2010-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7514221B2 (en) | 2000-04-20 | 2009-04-07 | St. Vincent's Hospital Sydney Limited | Diagnostic assay and method of treatment involving macrophage inhibitory cytokine-1 (MIC-1) |
US7141661B2 (en) | 2000-09-08 | 2006-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
US7276593B2 (en) | 2000-12-29 | 2007-10-02 | Curagen Corporation | Proteins and nucleic acids encoding same |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
WO2002072608A2 (en) | 2001-03-09 | 2002-09-19 | University Of Chicago | POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
RS51708B (en) | 2001-05-11 | 2011-10-31 | Amgen Inc. | Peptides and related molecules that bind to tall-1 |
GB0115195D0 (en) | 2001-06-21 | 2001-08-15 | Bae Systems Plc | Split-pin drill jig |
FI117667B (en) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | A pharmaceutical composition suitable for use in orthopedics and dentistry |
US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
PT1463751E (en) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albumin fusion proteins |
US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
CN1241946C (en) | 2002-07-01 | 2006-02-15 | 美国福源集团 | Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells |
AU2003295424A1 (en) | 2002-11-08 | 2004-06-03 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
EP2441466B1 (en) | 2004-04-13 | 2014-07-23 | St Vincent's Hospital Sydney Limited | MIC-1 inhibiting agent |
WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
CN101724071A (en) | 2004-10-08 | 2010-06-09 | 杜门蒂斯有限公司 | Single domain antibodies against TNFRl and methods of use therefor |
PT1844337E (en) | 2005-01-24 | 2014-04-03 | Pepscan Systems Bv | Binding compounds, immunogenic compounds and peptidomimetics |
JP2007258293A (en) | 2006-03-22 | 2007-10-04 | Fuji Electric Holdings Co Ltd | Device and method for solder wettability evaluation |
LT2004683T (en) | 2006-03-24 | 2016-10-10 | Biogen Hemophilia Inc. | Pc5 as a factor ix propeptide processing enzyme |
US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
AU2007254824A1 (en) | 2006-06-02 | 2007-12-13 | Wyeth | Use of proteins and peptides of the TGF-beta superfamily for purification and therapeutic methods |
AU2007277556B2 (en) | 2006-07-26 | 2012-11-29 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
KR101245877B1 (en) | 2006-08-04 | 2013-03-20 | 메디치니쉐 호흐슐레 하노버 | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
EP2144639B1 (en) | 2007-04-25 | 2012-08-22 | Stem Cells Spin S.A. | New stem cell line and its application |
BRPI0814465B1 (en) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | FUSION PROTEIN, DIMER, METHOD FOR PRODUCING A FUSION PROTEIN, CELL LINEAGE, USES OF A FUSION PROTEIN AND A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION |
ES2346178T3 (en) | 2007-07-31 | 2015-11-02 | Affibody Ab | New compositions, procedures and uses of albumin binding |
CN101854947A (en) | 2007-08-16 | 2010-10-06 | 圣文森特医院悉尼有限公司 | Be used to regulate active medicament of macrophage inhibition factor (MIC-1) and method |
AU2008310310A1 (en) | 2007-10-09 | 2009-04-16 | St Vincent's Hospital Sydney Limited | A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
CA2701945A1 (en) | 2007-10-22 | 2009-04-30 | Samuel Norbert Breit | Methods of prognosis of overall survival using mic-1 |
CN102066415A (en) * | 2007-10-29 | 2011-05-18 | 弗吉尼亚科技知识产权有限公司 | Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof |
SI2235064T1 (en) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
CN102037004A (en) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | Glycoconjugation of polypeptides using oligosaccharyltransferases |
EP2227696A1 (en) | 2008-01-08 | 2010-09-15 | Roche Diagnostics GmbH | Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15 |
MX2010010776A (en) * | 2008-03-31 | 2010-10-26 | Glaxo Group Ltd | Drug fusions and conjugates. |
JP2011523051A (en) | 2008-05-20 | 2011-08-04 | エフ.ホフマン−ラ ロシュ アーゲー | GDF-15 as a biomarker in type 1 diabetes |
WO2010007041A1 (en) | 2008-07-14 | 2010-01-21 | Roche Diagnostics Gmbh | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
US9012218B2 (en) | 2008-10-31 | 2015-04-21 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
WO2010048670A1 (en) | 2008-10-31 | 2010-05-06 | St Vincent's Hospital Sydney Limited | Method of prognosis in chronic kidney disease |
EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
JP5819733B2 (en) | 2009-02-12 | 2015-11-24 | ストライカー コーポレイションStryker Corporation | Peripheral administration of TGF-β superfamily member-containing protein for systemic treatment of disorders and diseases |
GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
DK3248610T3 (en) | 2009-05-05 | 2024-01-15 | Amgen Inc | FGF21 MUTANTS AND USES THEREOF |
MX2011013455A (en) | 2009-07-08 | 2012-02-13 | Amgen Inc | Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering. |
US20130323835A1 (en) | 2009-07-15 | 2013-12-05 | Zirus, Inc. | Mammalian Genes Involved in Infection |
US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
KR101968766B1 (en) | 2009-11-05 | 2019-04-12 | 제넨테크, 인크. | Methods and composition for secretion of heterologous polypeptides |
EA201890907A1 (en) | 2009-11-30 | 2020-04-30 | Янссен Байотек, Инк. | MUTED Fc ANTIBODIES WITH REMOVED EFFECTIVE FUNCTIONS |
WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
JP5791335B2 (en) | 2010-04-07 | 2015-10-07 | 花王株式会社 | Method for producing organopolysiloxane compound |
US20130202564A1 (en) | 2010-04-09 | 2013-08-08 | University Of Southern California | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration |
EP2383571A1 (en) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer |
ES2627337T3 (en) | 2010-08-26 | 2017-07-27 | F. Hoffmann-La Roche Ag | Use of biomarkers to control a medication in a subject suffering from heart failure |
EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
JP5977814B2 (en) * | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | Method for treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
SI2697257T1 (en) | 2011-04-13 | 2017-02-28 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
US9890218B2 (en) | 2011-06-30 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
MX2013014687A (en) | 2011-06-30 | 2014-02-17 | Genentech Inc | Anti-c-met antibody formulations. |
US9714276B2 (en) * | 2012-01-26 | 2017-07-25 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) polypeptides |
US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
WO2013192388A1 (en) | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
WO2014000042A1 (en) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
MX2015001675A (en) | 2012-08-08 | 2015-04-10 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof. |
AR094271A1 (en) | 2012-12-21 | 2015-07-22 | Aveo Pharmaceuticals Inc | ANTI-BODY ANTIBODIES |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
JP6272907B2 (en) | 2013-01-30 | 2018-01-31 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | Compositions and methods of use in the treatment of metabolic disorders |
TR201809571T4 (en) | 2013-03-15 | 2018-07-23 | Hoffmann La Roche | IL-22 polypeptides and IL-22 fc fusion proteins and methods of use. |
CN203123206U (en) * | 2013-04-01 | 2013-08-14 | 宋艳丽 | Simple disposable anti-pollution sterile injection syringe |
EA035319B1 (en) | 2013-07-31 | 2020-05-27 | Эмджен Инк. | STABILIZATION OF Fc-CONTAINING POLYPEPTIDES |
NZ754961A (en) | 2013-07-31 | 2022-04-29 | Amgen Inc | Growth differentiation factor 15 (gdf-15) constructs |
JP6704358B2 (en) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | Compositions and methods of use for treating metabolic disorders |
US9920118B2 (en) | 2014-10-31 | 2018-03-20 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
CN108367053A (en) | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | The method that metabolic disease is treated or improved using growth and differentiation factor 15 (GDF-15) |
-
2015
- 2015-07-28 JP JP2016576027A patent/JP6704358B2/en active Active
- 2015-07-28 AU AU2015296640A patent/AU2015296640B2/en active Active
- 2015-07-28 AP AP2016009663A patent/AP2016009663A0/en unknown
- 2015-07-28 CA CA2953827A patent/CA2953827A1/en active Pending
- 2015-07-28 MX MX2017000964A patent/MX370115B/en active IP Right Grant
- 2015-07-28 WO PCT/US2015/042510 patent/WO2016018931A1/en active Application Filing
- 2015-07-28 CR CR20170027A patent/CR20170027A/en unknown
- 2015-07-28 SG SG11201700378PA patent/SG11201700378PA/en unknown
- 2015-07-28 US US14/811,578 patent/US9834586B2/en active Active
- 2015-07-28 KR KR1020177002592A patent/KR20170065026A/en unknown
- 2015-07-28 SG SG10201802098UA patent/SG10201802098UA/en unknown
- 2015-07-28 MY MYPI2017700310A patent/MY192917A/en unknown
- 2015-07-28 TW TW104124401A patent/TWI710570B/en active
- 2015-07-28 MD MDA20170020A patent/MD20170020A2/en not_active Application Discontinuation
- 2015-07-28 ES ES15827485T patent/ES2883158T3/en active Active
- 2015-07-28 CN CN201580041716.9A patent/CN106573966B/en active Active
- 2015-07-28 PE PE2017000103A patent/PE20170771A1/en unknown
- 2015-07-28 UA UAA201700670A patent/UA123432C2/en unknown
- 2015-07-28 EP EP15827485.2A patent/EP3174894B1/en active Active
- 2015-07-28 TN TN2016000578A patent/TN2016000578A1/en unknown
- 2015-07-28 EA EA201692477A patent/EA035581B1/en unknown
-
2016
- 2016-12-27 IL IL249793A patent/IL249793B/en unknown
-
2017
- 2017-01-13 ZA ZA2017/00311A patent/ZA201700311B/en unknown
- 2017-01-24 PH PH12017500153A patent/PH12017500153A1/en unknown
- 2017-01-25 CL CL2017000201A patent/CL2017000201A1/en unknown
- 2017-01-25 DO DO2017000025A patent/DOP2017000025A/en unknown
- 2017-01-25 SV SV2017005367A patent/SV2017005367A/en unknown
- 2017-01-25 EC ECIEPI20175276A patent/ECSP17005276A/en unknown
- 2017-01-25 CO CONC2017/0000614A patent/CO2017000614A2/en unknown
- 2017-11-01 US US15/801,198 patent/US20180134761A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,877 patent/US11358995B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500153A1 (en) | Compositions and methods of use for treating metabolic disorders | |
PH12017500680A1 (en) | Compositions and methods of use for treating metabolic disorders | |
WO2014120619A3 (en) | Compositions and methods of use in treating metabolic disorders | |
EP3183005A4 (en) | Methods and compositions for the treatment of metabolic disorders | |
IL251371A0 (en) | Cortexolone 17alpha-benzoate for use in the treatment of tumours | |
MX2015017253A (en) | Compositions and methods for treating metabolic disorders. | |
IL242664A0 (en) | Ep catheter with trained support member, and related methods | |
MX2021010886A (en) | Medicaments for slowing parkinson's disease. | |
EP3137082A4 (en) | Methods to treat, prevent, and improve skin conditions | |
MX2019000677A (en) | B-cell-mimetic cells. | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
PH12017500084A1 (en) | Vitamin b2 and its use | |
MX2017000087A (en) | Novel rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer. | |
ZA201606113B (en) | Composition for relieving pain, stress and insomnia | |
MA39718A (en) | Compositions for treating skin conditions | |
PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
EP3169351A4 (en) | Use of hyaluronidase for treatment of muscle stiffness |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |